News

Filter

Current filters:

Afinitor

1 to 9 of 50 results

Scottish backing for Novartis’ Afinitor for kidney cancer patients

Scottish backing for Novartis’ Afinitor for kidney cancer patients

10-11-2014

The Scottish Medicines Consortium has issued a positive recommendation for Swiss pharma major Novartis’…

AfinitorClinical pharmacologyHealthHealth Medical PharmaNHSNovartisOncologyPharmaceuticalPricingRegulationUK

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga

28-09-2014

Swiss pharma major Novartis on Saturday presented final results on overall survival (OS) from a Phase…

AfinitorJanssenJohnson & JohnsonNovartisOncologyPharmaceuticalResearchSpainZytiga

Novartis breast cancer drug Afinitor not cost effective for NHS, says draft NICE guidance

08-07-2013

Swiss drug major Novartis' (NOVN: VX) breast cancer drug Afinitor (everolimus) is not recommended as…

AfinitorEuropeNovartisOncologyPharmaceuticalPricingRegulation

Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer

03-05-2013

A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast…

AfinitoreverolimusHerceptinNovartisOncologyPharmaceuticalResearchRochetrastuzumab

1 to 9 of 50 results

Back to top